This was partly offset by a 1% rise in the company’s revenue from $46 billion to $47 billion over the same period; and a 4.1% ...
If it does prove to be the end of emraclidine for schizophrenia, that looks set to benefit Bristol-Myers Squibb, which ended ...
Bristol-Myers Squibb Co (NYSE:BMY) shares are trading higher Monday. The stock appears to be reacting positively after AbbVie ...
Bristol-Myers Squibb Company ( NYSE: BMY) Guggenheim Securities Inaugural Healthcare Innovation Conference November 11, 2024 10:00 AM ET Samit Hirawat - EVP, Chief Medical Officer, Global Drug ...
Hosted on MSN14h
What's Behind the Insider Buying on This High-Yield Stock?The biopharma industry is on an upward trajectory, driven by groundbreaking advances in treatment options and a rising demand ...
Bristol-Myers Squibb Company is a global biopharmaceutical firm focused on discovering, developing, and delivering innovative medicines for a range of serious diseases. With a rich history dating ...
Bristol Myers Squibb (NYSE: BMY) recently reported its Q3 results, with revenues and earnings exceeding the street estimates.
The Associated Press on MSN11d
A promising schizophrenia drug showed mixed results. What does that mean for patients?Some people who took a new schizophrenia drug for one year improved with only a few side effects, but many dropped out of the ...
Key Takeaways The S&P 500 added 0.1% on Monday, Nov. 11, 2024, closing above the 6,000-point milestone as investors continued ...
Concluded targeted enrollment of Phase 3 INDIGO trial evaluating obexelimab for the treatment of Immunoglobulin G4-Related ...
**NM signifies a non meaningful value. A dash signifies the data is not available.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback